Oertel WH - Search Results

1

123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism.

Schwarz J, Tatsch K, Gasser T, Arnold G, Pogarell O, Künig G, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Mov Disord. 1998 Jan;13(1):16-9. doi: 10.1002/mds.870130107. Mov Disord. 1998. PMID: 9452320 Clinical Trial.

2

Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease.

Gasser T, Schwarz J, Arnold G, Trenkwalder C, Oertel WH. Gasser T, et al. Among authors: oertel wh. Arch Neurol. 1992 Nov;49(11):1131-4. doi: 10.1001/archneur.1992.00530350045017. Arch Neurol. 1992. PMID: 1444878

3

Marked reduction of striatal dopamine D2 receptors as detected by 123IBZM-SPECT in a Wilson's disease patient with generalized dystonia.

Schwarz J, Tatsch K, Vogl T, Kirsch CM, Trenkwalder C, Arnold G, Gasser T, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Mov Disord. 1992;7(1):58-61. doi: 10.1002/mds.870070111. Mov Disord. 1992. PMID: 1532631

4

123I-iodobenzamide-SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism.

Schwarz J, Tatsch K, Arnold G, Gasser T, Trenkwalder C, Kirsch CM, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Neurology. 1992 Mar;42(3 Pt 1):556-61. doi: 10.1212/wnl.42.3.556. Neurology. 1992. PMID: 1549216

5

SPECT imaging of dopamine D2 receptors with 123I-IBZM: initial experience in controls and patients with Parkinson's syndrome and Wilson's disease.

Tatsch K, Schwarz J, Oertel WH, Kirsch CM. Tatsch K, et al. Among authors: oertel wh. Nucl Med Commun. 1991 Aug;12(8):699-707. doi: 10.1097/00006231-199108000-00005. Nucl Med Commun. 1991. PMID: 1838142

6

Comparison of 123I-IBZM SPECT and 11C-raclopride PET findings in patients with parkinsonism.

Schwarz J, Antonini A, Tatsch K, Kirsch CM, Oertel WH, Leenders KL. Schwarz J, et al. Among authors: oertel wh. Nucl Med Commun. 1994 Oct;15(10):806-13. doi: 10.1097/00006231-199410000-00006. Nucl Med Commun. 1994. PMID: 7838444 Clinical Trial.

7

Clinical progressive supranuclear palsy: differential diagnosis by IBZM-SPECT and MRI.

Arnold G, Tatsch K, Oertel WH, Vogl T, Schwarz J, Kraft E, Kirsch CM. Arnold G, et al. Among authors: oertel wh. J Neural Transm Suppl. 1994;42:111-8. doi: 10.1007/978-3-7091-6641-3_9. J Neural Transm Suppl. 1994. PMID: 7964681

8

Treatment with D-penicillamine improves dopamine D2-receptor binding and T2-signal intensity in de novo Wilson's disease.

Schwarz J, Antonini A, Kraft E, Tatsch K, Vogl T, Kirsch CM, Leenders KL, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Neurology. 1994 Jun;44(6):1079-82. doi: 10.1212/wnl.44.6.1079. Neurology. 1994. PMID: 8208404

9

123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism.

Schwarz J, Tatsch K, Arnold G, Ott M, Trenkwalder C, Kirsch CM, Oertel WH. Schwarz J, et al. Among authors: oertel wh. Neurology. 1993 Dec;43(12 Suppl 6):S17-20. Neurology. 1993. PMID: 8264906

10

IBZM-SPECT as predictor for dopamimetic responsiveness of patients with de novo parkinsonian syndrome.

Oertel WH, Schwarz J, Tatsch K, Arnold G, Gasser T, Kirsch CM. Oertel WH, et al. Adv Neurol. 1993;60:519-24. Adv Neurol. 1993. PMID: 8420182

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

649 results

Search Page

Filters